Literature DB >> 1884747

Comparison of the bioavailability of two slow release preparations of disopyramide.

M G Bogaert1, F Belpaire, G De Wilde, R A Lefebvre.   

Abstract

The bioavailability of two slow release preparations of disopyramide has been compared in a randomized cross-over trial of Rythmodan L.A. 250 mg b.d. and Dirytmin Durettes 300 mg b.d., given to 10 healthy volunteers. The plasma concentrations of disopyramide were measured on the 5th day of each treatment period. With both preparations, plasma concentrations were well sustained. The amount absorbed was slightly lower after Rythmodan L.A. than after Dirytmin Durettes, but the fluctuations over a dosing interval were significantly more pronounced for Dirytmin Durettes than for Rythmodan L.A.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1884747     DOI: 10.1007/bf00279984

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  3 in total

1.  Use of confidence intervals in analysis of comparative bioavailability trials.

Authors:  W J Westlake
Journal:  J Pharm Sci       Date:  1972-08       Impact factor: 3.534

2.  Sustained release disopyramide compared to plain capsules after change-over from intravenous infusion.

Authors:  E Lien; O M Bakke
Journal:  Br J Clin Pharmacol       Date:  1983-07       Impact factor: 4.335

3.  Clinical pharmacokinetics of controlled-release disopyramide in patients with cardiac arrhythmias.

Authors:  E V Capparelli; D M DiPersio; H Zhao; J Kluger; M S Chow
Journal:  J Clin Pharmacol       Date:  1988-04       Impact factor: 3.126

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.